HE3235 Inhibits Growth of Castration-Resistant Prostate Cancer

HE3235 Inhibits Growth of Castration-Resistant Prostate Cancer

Treatments for advanced prostate cancer (CaP) typically involve androgen deprivation therapy. However, most patients eventually develop castration-resistant CaP (CRPC) for which highly effective therapies are limited. We explored the efficacy of a novel agent, HE3235, in inhibiting growth of CRPC i...

Full description

Bibliographic Details
Main Authors: Theodore D. Koreckij, Richard J. Trauger, Robert Bruce Montgomery, Tiffany E.M. Pitts, Ilsa Coleman, Holly Nguyen, Chris L. Reading, Peter S. Nelson, Robert L. Vessella, Eva Corey
Format: Article
Language:English
Published: Elsevier 2009-11-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558609800791

Internet

http://www.sciencedirect.com/science/article/pii/S1476558609800791

Similar Items